AMA, states sue Trump administration over Title X changes

The American Medical Association (AMA) filed suit against the Trump administration after it finalized changes to Title X that impact family planning providers.

The Title X program impacts roughly 4 million people, and the changes by the Trump administration impact how family providers that receive funding through the program can operate and what advice they can give their patients, according to the AMA. The final rule specifically requires financial and physical separation at family planning facilities where abortion services are offered that receive Title X funding. The final rule also includes a “gag rule” that forbids the referral of abortion as a method of family planning.

The AMA filed its lawsuit to block the new rule in the U.S. District Court in the District of Oregon, contending the rule violates patient rights under the Code of Medical Ethics.

“Because of the administration’s overreach and interference in healthcare decision making, physicians will be prohibited from having open, frank conversations with their patients about all their healthcare options. This blatant violation of patients’ rights under the Code of Medical Ethics is untenable,” AMA President Barbara L. McAneny, MD, said in a statement.

AMA is not the only one to jump into a legal battle over the final rule, which was published Feb. 22. Planned Parenthood––which receives an estimated $60 million in federal funding from Title X, according to The Washington Post––as well as 21 state attorneys general have filed lawsuits to challenge the rule. Industry groups are specifically taking aim at the prohibition against referrals for comprehensive reproductive care that includes abortion services.

The Trump-Pence administration’s gag rule is unethical, illegal, and dangerous, which is why Planned Parenthood is suing to protect patients’ rights and access to health care,” Leana Wen, MD, president of Planned Parenthood Federation of America, said in a statement. “Four million people receive care through Title X, our nation’s program for affordable birth control and reproductive health care, and for many of our patients, we are their only source of care for cancer screenings, birth control, and crucial preventive care.”

The Title X program primarily serves low-income patients––78 percent of Title X patients have incomes below 150 percent of the federal poverty level, according to HHS.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.